GamaMabs Pharma starts phase Ia/Ib study of first-in-class monoclonal antibody GM102 in advanced gynecological cancer 26 July 2016 Non classé, Press releases First trial of mAb targeting anti-Müllerian human receptor II tested in oncology patients Initial results expected in 2017 Read more